.png){kind=icon}
.png){kind=icon}
Return
Safety and efficacy of early antiplatelet therapy after intravenous thrombolysis for acute ischemic stroke: A comprehensive meta-analysis with trial sequential analysis
.png){kind=icon}
PRE
AI
H
A
M
A
A
N
A
O
J
DOI：10.1177/17474930261458007.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>Early antiplatelet therapy after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients may prevent re-occlusion and early neurological deterioration, but it could increase hemorrhagic transformation. Evidence remains conflicting, particularly with emerging contemporary trials.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>We conducted a Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guided systematic review of randomized controlled trials (RCTs) comparing early antiplatelet therapy (eAPT) initiated within 24 h after IVT (with or without thrombectomy) versus standard timing (>24 h), placebo, or no antiplatelet therapy (CRD420251276445). Random-effects models were used to estimate odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs). Trial sequential analysis, subgroup analyses, meta-regression, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty ratings were performed.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>
Twelve RCTs with 4595 patients were included. Early antiplatelet therapy led to higher non-significant odds of symptomatic intracranial hemorrhage (sICH; OR = 1.68, 95% CI = 0.94–3.01;
<jats:italic toggle="yes">I</jats:italic>
<jats:sup>2</jats:sup>
= 10.4%; GRADE moderate), and mortality (OR = 1.15, 95% CI = 0.83–1.58;
<jats:italic toggle="yes">I</jats:italic>
<jats:sup>2</jats:sup>
= 14.8%; GRADE moderate) but not intracranial hemorrhage (OR = 1.01, 95% CI = 0.64–1.60;
<jats:italic toggle="yes">I</jats:italic>
<jats:sup>2</jats:sup>
= 52.6%; GRADE low). Functional outcomes were not improved: Modified Rankin Scale (mRS) 0–1 (OR = 1.10, 95% CI = 0.83–1.46;
<jats:italic toggle="yes">I</jats:italic>
<jats:sup>2</jats:sup>
= 60.5%; GRADE low) and mRS 0–2 (OR = 1.27, 95% CI = 0.89–1.80;
<jats:italic toggle="yes">I</jats:italic>
<jats:sup>2</jats:sup>
= 73.4%; GRADE very low). Trial sequential analysis indicated evidence remains inconclusive. Agent-specific subgroup analyses suggested higher sICH with early aspirin (OR = 2.13, 95% CI = 1.02–4.45) and possible benefit for mRS 0–2 with tirofiban (OR = 2.07, 95% CI = 1.25–3.43).
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>Routine early antiplatelet therapy within 24 h after IVT does not provide conclusive functional benefit, and our analysis cannot exclude clinically meaningful hemorrhagic harm. Further adequately powered RCTs are needed to define whether any selected regimen—especially tirofiban—has a favorable risk–benefit profile.</jats:p>
</jats:sec>
Journal
IF:
8.7
Papers:
3.0K
Citations:
8.4K
Organization
Cited Papers